Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Kiniksa Pharmaceuticals International Plc shares valued at $820,000 were purchased by Ragosa Mark on Oct 28 ’25. At $41.00 per share, Ragosa Mark acquired 20,000 shares.
Also, Ragosa Mark purchased 20,000 shares, netting a total of over 820,000 in proceeds.
Before that, Patel Sanj K had sold 121,248 shares from its account. In a trade valued at $4,717,015, the CHAIRMAN & CEO traded Kiniksa Pharmaceuticals International Plc shares for $38.90 each. Upon closing the transaction, the insider’s holdings decreased to 121,248 shares, worth approximately $4.18 million.
As published in their initiating research note from TD Cowen on September 29, 2025, Kiniksa Pharmaceuticals International Plc [KNSA] has been a Buy and the price target has been revised to $60. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in mid March. As of September 13, 2024, Jefferies has initiated its “Buy” rating for KNSA. Earlier on May 03, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for KNSA stock.
Analyzing KNSA Stock Performance
On last trading session, Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] plunged -5.20% to $37.38. The stock’s lowest price that day was $36.8301, but it reached a high of $39.43 in the same session. During the last five days, there has been a drop of approximately -3.91%. Over the course of the year, Kiniksa Pharmaceuticals International Plc shares have jumped approximately 36.22%. Shares of the company reached a 52-week high of $42.05 on 10/28/25 and a 52-week low of $17.82 on 01/13/25.
Support And Resistance Levels for Kiniksa Pharmaceuticals International Plc (KNSA)
According to the 24-hour chart, there is a support level at 36.29, which, if violated, would cause prices to drop to 35.20. In the upper region, resistance lies at 38.95. The next price resistance is at 40.52. RSI (Relative Strength Index) is 46.30 on the 14-day chart, showing neutral technical sentiment.
Is Kiniksa Pharmaceuticals International Plc subject to short interest?
Stocks of Kiniksa Pharmaceuticals International Plc saw a sharp rise in short interest on 2025-10-15 jumping by 0.13 million shares to 2.56 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 2.43 million shares. A jump of 4.95% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.45 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.45.
Which companies own the most shares of Kiniksa Pharmaceuticals International Plc (KNSA)?
In terms of Kiniksa Pharmaceuticals International Plc share price expectations, FactSet research, analysts set an average price target of 54 in the next 12 months, up nearly 36.95% from the previous closing price of $39.43. Analysts anticipate Kiniksa Pharmaceuticals International Plc stock to reach 55 by 2025, with the lowest price target being 44. In spite of this, 1 analysts ranked Kiniksa Pharmaceuticals International Plc stock as Buy at the end of 2025. On June 29, 2020, BofA Securities assigned a price target of “a Buy” to the stock and reiterated coverage with a $40.
